Recent News from (OTC: MPSYF)
| MorphoSys AG Reports Second Quarter 2018 Financial Results|
|PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 1, 2018 / The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U.S. footprint to prepare for commercialization in the U.S. Conference call and webcast (in English) to be held on A...|
| Date: August, 01 2018 16:25|
| MorphoSys to Host Q2 2018 Conference Call on August 2, 2018|
|PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYF; NASDAQ: MOR) will publish its first six months' 2018 results on August 1 st , 2018 at 10:00 p.m. CEST (4 p.m. EDT; 9 p.m. BST). The Management team of Morpho...|
| Date: July, 25 2018 08:30|
| SA Stock To Watch: Netflix To The Rescue?|
|Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Netflix (NFLX) is set to report earnings after the bell on Monday. Analyst have pus...|
| Date: April, 14 2018 08:32|
| U.S. IPO Week Ahead: Subscription Unicorn Zuora Kicks Off The Q2 IPO Market|
|The first two IPOs of the second quarter are targeting a combined $170 million in the week ahead. Subscription billing unicorn Zuora (ZUO) and Alzheimer's disease biotech Alzheon (ALZH) represent the leading sectors from the first quarter. Tech deals are up 20% on average year-to-date; whi...|
| Date: April, 07 2018 10:18|
| MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2017 Results - Earnings Call Transcript|
|MorphoSys AG (MPSYF) Q4 2017 Results Earnings Conference Call March 13, 2018 9:00 a.m. ET Executives Simon Moroney - Chief Executive Officer Jens Holstein - Chief Financial Officer Malte Peters - Chief Development Officer Alexandra Goller - Associate Director, Corporate Communi...|
| Date: March, 13 2018 16:42|
Last 5 Days Trading Activity
Last 5 Days Short Activity
* Short Mode
Short Analysis provided by Squeeze Report. Get a complete short report on MPSYF.
About MorphoSys AG (OTC: MPSYF)
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. lt br / gt lt br / gt Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. lt br / gt lt br / gt Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. lt br / gt lt br / gt MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.
- Simon Moroney / CEO
- Jens Holstein / CFO
- Claudia GutjahrLoser / VP, Corp. Comm., VP, Investor Rel.
- Arndt Schottelius / Chief Development Officer
Current Share Structure
- Market Cap: $2,451,769,673 - 03/16/2018
- Issue and Outstanding: 22,935,170 - 03/31/2011
Recent Filings from (OTC: MPSYF)
|Filing Type: CT ORDER||Filing Source: edgar|
| Filing Date: April, 19 2018|
Daily Technical Chart for (OTC: MPSYF)
Stay tuned for daily updates and more on (OTC: MPSYF)
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter
More to come on (OTC: MPSYF)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MPSYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MPSYF and does not buy, sell, or trade any shares of MPSYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/